Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Arena Ready For FDA To Reconsider Weight-Loss Drug Lorcaserin

04 Jan 2012

• By Shirley Haley

Related Content

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

03 Jun 2011

Arena Must Deal With Rat Neoplasms To Move Forward With <i>Lorqess</i>

20 Sep 2010

Approvability Of Arena's Lorcaserin Still Unclear

09 Nov 2010

FDA Issues Complete Response Letter for Arena's Lorcaserin

24 Oct 2010

Qnexa’s Second Advisory Committee Review: Smaller Indication, Still Big Safety Questions

23 Dec 2011

Obesity Drug Developers Aim To Navigate Regulatory Backroads

01 Apr 2011

Related Companies

Arena Pharmaceuticals, Inc.

Eisai Co., Ltd.

Vivus, Inc.

Orexigen Therapeutics, Inc.

Additional Topics

Advisory Committees Regulation Drug Approval Standards BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.